Comparison of the EORTC QLQ-BM22 and the FACT-BP for assessment of quality of life in cancer patients with bone metastases

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 2, 2012, Pages 213-219

  Popovic, Marko ^a   Nguyen, Janet ^a   Chen, Emily ^a   Di Giovanni, Julia ^a   Zeng, Liang ^a   Chow, Edward ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

advanced cancer; bone metastases; EORTC QLQ BM22; FACT BP; quality of life

Indexed keywords

BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PATIENT; COMPARATIVE EFFECTIVENESS; CONSTRUCT VALIDITY; CONTROLLED STUDY; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY; HUMAN; INSTRUMENT VALIDATION; INTERNAL CONSISTENCY; PAIN ASSESSMENT; PATIENT ASSESSMENT; PROCESS DEVELOPMENT; PSYCHOMETRY; PSYCHOSOCIAL CARE; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE; QUESTIONNAIRE; REVIEW; SCORING SYSTEM; SENSITIVITY ANALYSIS; TEST RETEST RELIABILITY;

BONE NEOPLASMS; CHRONIC PAIN; HUMANS; NEOPLASMS; PALLIATIVE CARE; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 84859450855     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.99     Document Type: Review

References (20)

1. Chow E, Nguyen J, Zhang L et al. International field-testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer 118(5), 1457-1465 (2012).
2. Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone 12(Suppl. 1), S9-S10 (1991).
3. Chow E, Bottomley A. Understanding the EORTC QLQ-BM22, the module for patients with bone metastases. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 461-465 (2009).
4. American Cancer Society. Cancer Facts and Figures, 1997. American Cancer Society, Atlanta, GA, USA (1997).
5. Harrington KD. Prophylactic management of impending fractures. In: Orthopedic Management of Metastatic Bone Disease. Harrington KD (Ed.). CV Mosby, MO, USA, 283-307 (1988).
6. Soni MK, Cella D. Quality of life and symptom measures in oncology: an overview. Am. J. Manage. Care 8, S560-S573 (2002). (Pubitemid 36096928)
7. Chow E, Hird A, Velikova G et al. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur. J. Cancer 45, 1146-1152 (2009).
8. Sneeuw KC, Aaronson NK, Osoba D et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med. Care 35, 490-506 (1997). (Pubitemid 127455047)
9. Gotay CC. Assessing cancer-related quality of life across a spectrum of applications. J. Natl Cancer Inst. Monogr. 33, 126-133 (2004).
10. Taphoorn MJ, Claassens L, Aaronson NK et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur. J. Cancer 46, 1033-1040 (2010).
11. Brady MJ, Cella DF, Mo F et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J. Clin. Oncol. 15, 974-986 (1997). (Pubitemid 27106280)
12. Caissie A, Culleton S, Nguyen J et al. EORTC QLQ-C15-PAL quality of life scores in patients with advanced cancer referred for palliative radiotherapy. Support Care Cancer doi:10.1007/s00520-011-1160- 6 (2011) (Epub ahead of print).
13. Zeng L, Sahgal A, Zhang L et al. Patterns of pain and functional improvement in patients with bone metastases after conventional external beam radiotherapy and a telephone validation study. Pain Res. Treat. 2011, 601720 (2011).
14. Ahlner-Elmqvist M, Bjordal K, Jordhoy MS et al. Characteristics and implications of attrition in health-related quality of life studies in palliative care. Palliat. Med. 23, 432-440 (2009).
15. Broom R, Du H, Clemons M et al. Switching breast cancer patients with progressive bone metastases to third- generation bisphosphonates: measuring impact using the functional assessment of cancer therapy-bone pain. J. Pain Symptom Manage. 38(2), 244-257 (2009).
16. Cella DF, Tusky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 11, 570-579 (1993). (Pubitemid 23071057)
17. Rodary C, Pezet-Langevin V, Garcia-Acosta S et al. Patient preference for either the EORTC QLQ-C30 or the FACIT quality of life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur. J. Cancer 40, 521-528 (2004). (Pubitemid 38220768)
18. Clemons MJ, Dranitsaris G, Ooi WS et al. Phase 2 trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J. Clin. Oncol. 24, 4895-4900 (2006). (Pubitemid 46630917)
19. Clemons M, Dranitsaris G, Ooi WS et al. A Phase 2 trial evaluating the palliative benefit of second line oral ibandronate in breast cancer patients with either a skeletal-related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res. Treat. 108, 79-85 (2008). (Pubitemid 351623243)
20. Harris K, Chow E, Zhang L et al. Patients' and healthcare professionals' evaluation of health-related quality of life issues in bone metastases. Eur. J. Cancer 45, 2510-2518 (2009).